Neurocrine Biosciences Inc (NBIX)
$126.79 -$1.10 (-0.86%) 4:38 PM 12/12/24
NASDAQ | $USD | Drug Manufacturers - Specialty & GenericStock Data
-
Market Cap
$12.97B -
Day's Range
$127.11 - $128.63 -
Volume
771,633 -
52 Week Low / High
$110.95 - $157.98 -
PE Ratio
34.17x -
PEG Ratio
0.30 -
Dividend Frequency
-
- Capital Growth
- Dividend Return to Date
- Dividend Payout year Est.
- Expenses
- Total Return
- Total Return %
- 15
- Strong Buy
- 8
- Buy
- 4
- Hold
- 0
- Sell
- 0
- Strong Sell
- $133.45
- Target Price
Company News
-
Exploring Three High Growth Tech Stocks in the United States — Oct 11th, 2024
Over the last 7 days, the United States market has risen by 1.2%, and in the past year, it has climbed an impressive 32%, with earnings expected to grow by 16% per annum over the next few years. In this context of robust market performance, identifying high growth tech stocks involves asse...
-
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results — Oct 9th, 2024
Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a...
-
Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? — Oct 16th, 2024
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds.In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against the other promising biotech stocks. Biotechnology stocks are known for their high ri...
-
KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment of Huntington's Disease Chorea Findings Presented at the 2024 MDS International Congress ...
-
Neurocrine Biosciences (NASDAQ:NBIX) has had a rough three months with its share price down 18%. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. Specifically, we decided to study Neurocrine Biosciences' R...
-
Neurocrine Biosciences (NASDAQ:NBIX) has had a rough three months with its share price down 18%. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. Specifically, we decided to study Neurocrine Biosciences' R...
-
Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? — Oct 16th, 2024
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds.In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against the other promising biotech stocks. Biotechnology stocks are known for their high ri...
-
Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? — Oct 16th, 2024
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds.In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against the other promising biotech stocks. Biotechnology stocks are known for their high ri...
-
Exploring Three High Growth Tech Stocks in the United States — Oct 11th, 2024
Over the last 7 days, the United States market has risen by 1.2%, and in the past year, it has climbed an impressive 32%, with earnings expected to grow by 16% per annum over the next few years. In this context of robust market performance, identifying high growth tech stocks involves asse...
-
Exploring Three High Growth Tech Stocks in the United States — Oct 11th, 2024
Over the last 7 days, the United States market has risen by 1.2%, and in the past year, it has climbed an impressive 32%, with earnings expected to grow by 16% per annum over the next few years. In this context of robust market performance, identifying high growth tech stocks involves asse...
-
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results — Oct 9th, 2024
Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a...
-
Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? — Oct 16th, 2024
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds.In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against the other promising biotech stocks. Biotechnology stocks are known for their high ri...
-
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results — Oct 9th, 2024
Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a...
-
Neurocrine Biosciences (NASDAQ:NBIX) has had a rough three months with its share price down 18%. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. Specifically, we decided to study Neurocrine Biosciences' R...
-
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results — Oct 9th, 2024
Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a...
-
Exploring Three High Growth Tech Stocks in the United States — Oct 11th, 2024
Over the last 7 days, the United States market has risen by 1.2%, and in the past year, it has climbed an impressive 32%, with earnings expected to grow by 16% per annum over the next few years. In this context of robust market performance, identifying high growth tech stocks involves asse...
-
KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment of Huntington's Disease Chorea Findings Presented at the 2024 MDS International Congress ...
-
Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? — Oct 16th, 2024
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds.In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against the other promising biotech stocks. Biotechnology stocks are known for their high ri...
-
Neurocrine Biosciences (NASDAQ:NBIX) has had a rough three months with its share price down 18%. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. Specifically, we decided to study Neurocrine Biosciences' R...
-
Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? — Oct 16th, 2024
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds.In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against the other promising biotech stocks. Biotechnology stocks are known for their high ri...
-
Neurocrine Biosciences (NASDAQ:NBIX) has had a rough three months with its share price down 18%. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. Specifically, we decided to study Neurocrine Biosciences' R...
-
Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? — Oct 16th, 2024
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds.In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against the other promising biotech stocks. Biotechnology stocks are known for their high ri...
-
KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment of Huntington's Disease Chorea Findings Presented at the 2024 MDS International Congress ...
-
Neurocrine Biosciences (NASDAQ:NBIX) has had a rough three months with its share price down 18%. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. Specifically, we decided to study Neurocrine Biosciences' R...
-
Neurocrine Biosciences (NASDAQ:NBIX) has had a rough three months with its share price down 18%. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. Specifically, we decided to study Neurocrine Biosciences' R...
-
Exploring Three High Growth Tech Stocks in the United States — Oct 11th, 2024
Over the last 7 days, the United States market has risen by 1.2%, and in the past year, it has climbed an impressive 32%, with earnings expected to grow by 16% per annum over the next few years. In this context of robust market performance, identifying high growth tech stocks involves asse...
-
KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment of Huntington's Disease Chorea Findings Presented at the 2024 MDS International Congress ...
-
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results — Oct 9th, 2024
Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a...
-
Exploring Three High Growth Tech Stocks in the United States — Oct 11th, 2024
Over the last 7 days, the United States market has risen by 1.2%, and in the past year, it has climbed an impressive 32%, with earnings expected to grow by 16% per annum over the next few years. In this context of robust market performance, identifying high growth tech stocks involves asse...
-
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results — Oct 9th, 2024
Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a...
-
KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment of Huntington's Disease Chorea Findings Presented at the 2024 MDS International Congress ...
-
Is Neurocrine Biosciences, Inc. (NBIX) the Most Promising Biotech Stock According to Hedge Funds? — Oct 16th, 2024
We recently compiled a list of the 10 Most Promising Biotech Stocks According to Hedge Funds.In this article, we are going to take a look at where Neurocrine Biosciences, Inc. (NASDAQ:NBIX) stands against the other promising biotech stocks. Biotechnology stocks are known for their high ri...
-
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results — Oct 9th, 2024
Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a...
-
Exploring Three High Growth Tech Stocks in the United States — Oct 11th, 2024
Over the last 7 days, the United States market has risen by 1.2%, and in the past year, it has climbed an impressive 32%, with earnings expected to grow by 16% per annum over the next few years. In this context of robust market performance, identifying high growth tech stocks involves asse...
-
Exploring Three High Growth Tech Stocks in the United States — Oct 11th, 2024
Over the last 7 days, the United States market has risen by 1.2%, and in the past year, it has climbed an impressive 32%, with earnings expected to grow by 16% per annum over the next few years. In this context of robust market performance, identifying high growth tech stocks involves asse...
-
KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment of Huntington's Disease Chorea Findings Presented at the 2024 MDS International Congress ...
-
Neurocrine Biosciences (NASDAQ:NBIX) has had a rough three months with its share price down 18%. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. Specifically, we decided to study Neurocrine Biosciences' R...
-
Neurocrine Biosciences (NASDAQ:NBIX) has had a rough three months with its share price down 18%. However, stock prices are usually driven by a company’s financials over the long term, which in this case look pretty respectable. Specifically, we decided to study Neurocrine Biosciences' R...
-
Neurocrine Biosciences Announces Conference Call and Webcast of Third Quarter 2024 Financial Results — Oct 9th, 2024
Conference Call and Webcast Scheduled for Wednesday, October 30 SAN DIEGO, Oct. 9, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) announced today that it has scheduled its third quarter 2024 financial results conference call and webcast for 5:00 a.m. Pacific Time (8:00 a...
-
KINECT®-HD2 Is the First Prospective Clinical Trial to Include Patients Taking Antipsychotic Medication in a Study Evaluating a Vesicular Monoamine Transporter 2 (VMAT2) Inhibitor for the Treatment of Huntington's Disease Chorea Findings Presented at the 2024 MDS International Congress ...
Portfolio
Comprised of 1 portfolios